“The authors reported that among #COVID19 patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

“The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally.

“The review will consider data collected so far in the Solidarity Trial and, in particular robust randomised available data, to adequately evaluate the potential benefits and harms from this drug

“The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the data is reviewed by the Data Safety Monitoring Board.

“The other arms of the trial are continuing.

“This concern relates to the use of hydroxychloroquine and chloraquine in #COVID19.

“I wish to reiterate that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria.

“WHO will provide further updates as we know more.

“And we will continue to work night and day for solutions, science and solidarity”